NO3099307T3 - - Google Patents

Info

Publication number
NO3099307T3
NO3099307T3 NO15702549A NO15702549A NO3099307T3 NO 3099307 T3 NO3099307 T3 NO 3099307T3 NO 15702549 A NO15702549 A NO 15702549A NO 15702549 A NO15702549 A NO 15702549A NO 3099307 T3 NO3099307 T3 NO 3099307T3
Authority
NO
Norway
Application number
NO15702549A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50287713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3099307(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3099307T3 publication Critical patent/NO3099307T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
NO15702549A 2014-01-29 2015-01-27 NO3099307T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1401465.8A GB201401465D0 (en) 2014-01-29 2014-01-29 Use of cladribine for treating autoimmune inflammatory disease
PCT/GB2015/050177 WO2015114315A1 (fr) 2014-01-29 2015-01-27 Utilisation de cladribine pour traiter la neuromyélite optique

Publications (1)

Publication Number Publication Date
NO3099307T3 true NO3099307T3 (fr) 2018-03-17

Family

ID=50287713

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15702549A NO3099307T3 (fr) 2014-01-29 2015-01-27

Country Status (19)

Country Link
US (1) US10350231B2 (fr)
EP (1) EP3099307B2 (fr)
JP (1) JP6535678B2 (fr)
AU (1) AU2015212613B2 (fr)
CA (1) CA2937978C (fr)
CY (1) CY1120139T1 (fr)
DK (1) DK3099307T3 (fr)
EA (1) EA031244B1 (fr)
ES (1) ES2655291T5 (fr)
GB (1) GB201401465D0 (fr)
HR (1) HRP20180071T4 (fr)
HU (1) HUE036120T2 (fr)
LT (1) LT3099307T (fr)
NO (1) NO3099307T3 (fr)
PL (1) PL3099307T5 (fr)
PT (1) PT3099307T (fr)
RS (1) RS56727B2 (fr)
SI (1) SI3099307T2 (fr)
WO (1) WO2015114315A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017394032B8 (en) 2017-01-21 2020-10-22 Guangzhou Hanfang Pharmaceutical Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP3628310A1 (fr) * 2018-09-25 2020-04-01 Synbias Pharma AG Composition pharmaceutique comprenant des dispersions solides de cladribine amorphe et support hydrosoluble pharmaceutiquement acceptable
CN113939532A (zh) * 2019-04-24 2022-01-14 维埃拉生物股份有限公司 使用抗cd19抗体治疗自身免疫性疾病
WO2022094334A1 (fr) * 2020-10-29 2022-05-05 Viela Bio, Inc. Utilisation d'un anticorps anti-cd19 pour traiter une maladie auto-immune
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2023242285A1 (fr) 2022-06-15 2023-12-21 Vektor Pharma Tf Gmbh Formulation sublinguale de composé anticancéreux destinée à être utilisée dans le traitement de maladies neurodégénératives auto-immunes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (fr) 1984-08-06 1990-05-29 Brigham Young University Preparation de composes a base de 2'-desoxyadenosine
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
AU2004226435B2 (en) 2003-03-28 2009-11-12 Ares Trading S.A. Cladribine formulations for improved oral and transmucosal delivery
DK3332789T3 (da) * 2004-12-22 2022-07-11 Merck Serono Sa Cladribinkur til behandling af multipel sklerose
EP4137819A1 (fr) 2007-02-08 2023-02-22 Biogen MA Inc. Compositions et leurs utilisations pour le traitement de la sclérose en plaques
US20100239580A1 (en) 2007-11-12 2010-09-23 Area Trading S.A. Taci-immunoglobulin fusion proteins for treatment of optic neuritis
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US9364534B2 (en) 2009-09-15 2016-06-14 Csl Limited Treatment of neurological conditions
EP2343075A1 (fr) 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxyde à utiliser dans le traitement d'une maladie de démyélinisation auto-immune du système nerveux central (SNC)

Also Published As

Publication number Publication date
EP3099307B1 (fr) 2017-10-18
AU2015212613A1 (en) 2016-09-01
CA2937978C (fr) 2022-08-16
WO2015114315A1 (fr) 2015-08-06
EA031244B1 (ru) 2018-12-28
PL3099307T5 (pl) 2020-11-30
RS56727B2 (sr) 2020-11-30
EP3099307B2 (fr) 2020-07-29
LT3099307T (lt) 2018-02-12
JP6535678B2 (ja) 2019-06-26
RS56727B1 (sr) 2018-03-30
SI3099307T2 (sl) 2020-11-30
HRP20180071T1 (hr) 2018-02-23
EP3099307A1 (fr) 2016-12-07
PL3099307T3 (pl) 2018-03-30
SI3099307T1 (en) 2018-02-28
ES2655291T5 (es) 2021-05-06
CA2937978A1 (fr) 2015-08-06
DK3099307T3 (en) 2018-01-22
GB201401465D0 (en) 2014-03-12
JP2017504636A (ja) 2017-02-09
US20160339049A1 (en) 2016-11-24
ES2655291T3 (es) 2018-02-19
US10350231B2 (en) 2019-07-16
PT3099307T (pt) 2018-01-08
HRP20180071T4 (hr) 2020-10-16
EA201691525A1 (ru) 2016-12-30
CY1120139T1 (el) 2018-12-12
HUE036120T2 (hu) 2018-06-28
AU2015212613B2 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
BR112016027648A2 (fr)
BR112016021153A2 (fr)
BR112016021943A2 (fr)
BR112016021815A2 (fr)
BR112016027956A2 (fr)
BR112016027384A2 (fr)
BR112016018824A2 (fr)
BR112016018327A2 (fr)
BR112016026037A2 (fr)
BR112016023273A2 (fr)
BR112016023215A2 (fr)
BR112016026013A2 (fr)
BR112016020177A2 (fr)
BR112016017262A2 (fr)
BR112016018185A2 (fr)
BR112016018575A2 (fr)
BR112016020070A2 (fr)
BR112016016992A2 (fr)
BR112016018043A2 (fr)
BR112016030631A2 (fr)
BR112016017681A2 (fr)
BR112016023451A2 (fr)
BR112016027217A2 (fr)
BR112016020204A2 (fr)
BR112016028013A2 (fr)